n° 165 | September 2022
In this issue:

Europe recommends screening programmes for prostate cancer

Long campaign by Europa Uomo bears fruit
20 Sep 2022

Europa Uomo gets quality of life and awareness on the agenda

Representatives give patient perspective at ESMO Congress 2022
16 Sep 2022

New backing for organised screening comes in European male cancer report

Male-targeted approaches can help change behaviours
31 Aug 2022

Annual screening could be particularly important for Black men

American research suggests regular PSA tests reduce mortality
24 Aug 2022
Prostate Research and Treatments

Testing the combination of talazoparib and enzalutamide in men with mCRPC

This article reports on the design of an ongoing research study (also known as a clinical trial) called TALAPRO-2. The TALAPRO-2 trial is testing the combination of two medicines called talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer.

The combination of talazoparib plus enzalutamide will be compared with enzalutamide plus placebo. Enzalutamide is approved to treat men with prostate cancer. Talazoparib is not approved to treat men with prostate cancer.

Read the full article here.


Prostate cancer now New Zealand’s most diagnosed cancer

Prostate cancer is now New Zealand’s most diagnosed cancer and one in eight men will get prostate cancer in their lifetime.

Read more here.

Active surveillance for low-risk prostate cancer continues to rise

Until about 10 years ago, most men diagnosed with prostate cancer that has a low risk of causing death had immediate treatment with surgery or radiation.

A recent study confirms that men are increasingly opting against immediate treatment. Instead, they are working with their doctors to carefully monitor the cancer via a process known as active surveillance, holding off on treatment until there are signs of progression.

Read more here.

Serum PSA-based early detection of prostate cancer in Europe

Now that Europe recommends screening programmes for prostate cancer (see article at the top of this Update) early detection is becoming very important.

Read here the article by H. Van Poppel et al. ‘Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future‘.


Europa Uomo News

In memoriam Ekke Buchler

With great sadness, we have received the news of the death of Ekke Büchler, 19.07.1941 – 04.09.2022, chairman of our Austrian member group ‘Selbsthilfe Prostatakrebs’ who has lost the battle against lung cancer.

See the funeral card here.

Europa Uomo has expressed their condolences to Ekke’s family. It was a great honour to have known Ekke and he will be sadly missed in Europa Uomo.




Europa Uomo's fifth webinar on active surveillance

Led by Cosimo Pieri and Tania Estapé – Board members Europa Uomo

Presentation of the Prostate Predict tool by Professor Vincent J Gnanapragasam (University Professor of Urology, University of Cambridge, and Honorary Consultant Urologist, Cambridge University Hospitals)

Wednesday 26th October 2022, 6 to 7 pm CET

Zoom-link: https://us02web.zoom.us/j/9212308719?pwd=SVZmSVhlcGZ3c2FNZEhzUm5Sa1grUT09



  • Welcome
  • In this webinar, Europa Uomo will focus on the new support that may be given using new on line and free to use tools to support the patient/urologist conversation at the time of critical decision-making in cases where active surveillance may be considered versus other treatments. We have invited one of the researchers in this area to talk about new ways of adding support during decision-making.
  • What is the new information that is offered by Predict Prostate to support critical decision-making?
  • In what situations might active surveillance be an effective strategy and how does Predict Prostate help in making decisions?
  • How does the Predict Prostate tool help to balance the value of treatment against other factors like a man’s age and other illnesses?
  • What information was used to develop this tool?
  • How reliable and robust are the estimates it provides and what is the evidence that it makes a difference?
  • What are the limits of this application in critical moments of decision-making?
  • What types of prostate cancer is this not suitable for?
  • Questions and answers
Items of Interest

Webinars on active surveillance

In August, Active Surveillance Patients International organised a webinar on “How and when should I do a genetics test?”. You can now view a recording of the event.

In September, they have organised a webinar on “Active Surveillance 101”. Click here to view a recording of the event.

Patients in the USA are paying more out-of-pocket costs for cancer care

An American study provides new evidence of the growing financial burden for non-elderly patients with cancer with private health insurance coverage.

For prostate cancer patients, the study results showed an significantly increase of 4% for the total mean costs per patient.

Read the press release here.

Pelvic floor therapy

EUPROMS 1.0 and EUPROMS 2.0 showed clearly that continence is a major obstacle for patients after surgery. Training of the pelvic floor is essential to maintain or get a successful status of continence.

The above studies show that this unfortunately seems to be not the case with many patients. To assist this there are a variety of points available, one of the is the MAPLe high definition technology. For more information please refer to http://www.novuqare.com/eng/


All previous issues are available on website: www.europa-uomo.org/newsletters/